echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Clinica Chimica Acta: Retrospective study of clinical characteristics and prognostic time dependence changes in hospitalized COVID-19 patients in Wuhan.

    Clinica Chimica Acta: Retrospective study of clinical characteristics and prognostic time dependence changes in hospitalized COVID-19 patients in Wuhan.

    • Last Update: 2020-08-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, 2019 coronavirus disease (COVID-19) continued to erupt worldwide.
    but the clinical symptoms and prognosis of COVID-19 patients are not clear.
    divided 843 COVID-19 patients admitted between 22 January and 14 February 2020 into three groups, depending on the onset of the initial clinical symptoms: Group A (21 January to 25 January, n - 324), and Group B (26 January to 26 January).
    31 January, n , 358) and Group C (1 February to 10 February, n , 161).
    collect data on demographics, symptoms, first laboratory test results, treatment and results (within 12 days of hospitalization).
    results showed that the median duration from onset of symptoms to hospitalization decreased over time (13 days, 10 days and 5 days, p.lt;0.05, respectively).
    group C had fewer fever symptoms and bilateral pneumonia than in Group A and Group B.
    laboratory results showed lower levels of white blood cells, neutrophils and platelets, lactic acid and D-dipolymers, and higher counts in lymphocytes, CD3 and CD8 C groups.
    in addition, there were fewer mild-moderate and severe cases in Group C than in the other two groups.
    importantly, the incidence of complications (18.5 per cent, 14.2 per cent and 11.2 per cent, respectively, p.lt;0.05) and all-cause mortality (11.7 per cent, 8.4 per cent and 5.6 per cent, respectively) decreased over time.
    the clinical characteristics and prognostication over time in patients with COVID-19.
    improved at a later stage of discovery.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.